Article Data

  • Views 1189
  • Dowloads 141

Case Reports

Open Access

Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel

  • K. Takeuchi1,*,
  • M. Fujimoto1
  • T. Tsujino1
  • Y. Takeda2
  • S. Yoshida3

1Department of Obstetrics and Gynecology, Hyogo Prefectural Tsukaguchi Hospital, Japan

2Department of Pathology, Hyogo Prefectural Tsukaguchi Hospital, Japan

3Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Japan

DOI: 10.12892/ejgo200704322 Vol.28,Issue 4,July 2007 pp.322-323

Published: 10 July 2007

*Corresponding Author(s): K. Takeuchi E-mail:

Abstract

Background: The results of treatment of malignant peritoneal mesothelioma are quite unsatisfactory, especially in the later stages of the disease, regardless of the treatment modality employed.

Case: We report a case of locally advanced malignant peritoneal mesothelioma, in which the combination of radiotherapy and intraperitoneal paclitaxel was beneficial for long-term disease stabilization. A 71-year-old woman presented with abdominal pain. Abdominal ultrasound and magnetic resonance imaging confirmed the presence of a mass with both cystic and solid components with moderate ascites. Serum CA-125 concentration was 727 IU/ml. At exploratory laparotomy, a large mass originating from the pouch of Douglas was found. A total abdominal hysterectomy and bilateral salpingo-oophorectomy was performed with partial excision of the mass and involved the peritoneum of the pouch of Douglas. The histologic study showed malignant peritoneal mesothelioma. One year and five months after surgery, significant progression of the residual tumor with increasing ascites was noted. Radiotherapy to the whole pelvis with 45 Gy in 25 fractions was given over five weeks together with intraperitoneal paclitaxel (60 mg/m2) instillation, which was repeated every three weeks. The patient received eight cycles of paclitaxel instillation over seven months. The compliance of the patient was excellent under therapy and her general condition improved significantly one and half year with a marked regression of the tumor masses after this treatment.

Conclusion: The combination of radiotherapy and intraperitoneal paclitaxel seems suitable in palliative settings primarily aimed at improving the quality of life.

Keywords

Malignant peritoneal mesothelioma; Radiotherapy; Intraperitoneal paclitaxel

Cite and Share

K. Takeuchi,M. Fujimoto,T. Tsujino,Y. Takeda,S. Yoshida. Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel. European Journal of Gynaecological Oncology. 2007. 28(4);322-323.

References

[1] Sridhar K.S., Doria R., Raub W.A. Jr, Thurer R.J., Saldana M.: "New strategies are needed in diffuse malignant mesothelioma". Cancer, 1992, 70, 2969.

[2] Sugarbaker P.H., Yan T.D., Stuart 0.A., Yoo D.: "Comprehensive management of diffuse malignant peritoneal mesothelioma". Eur. J. Surg. Oneal., 2006, 32, 686.

[3] Sugarbaker P.H., Acherman Y.I., Gonzalez-Moreno S., OrtegaPerez G., Stuart O.A., Marchettini P.: "Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience". Semin. Oneal., 2002, 29, 51.

[4] Kerrigan S.A., Turnnir R.T., Clement P.B., Young R.H., Churg A.: "Diffuse malignant epithelial mesotheliomas of the peritoneum in women: a clinicopathologic study of 25 patients". Cancer, 2002, 94, 378.

[5] Baldini E.H.: "External beam radiation therapy for the treatment of pleural mesothelioma". Thorac. Surg. Clin., 2004, 14, 543.

[6] Bissett D., Macbeth F.R., Cram I.: "The role of palliative radiotherapy in malignant mesothelioma". Clin. Oneal. (R. Coll. Radial.), 1991, 3, 315.

[7] Ball D.L., Cruickshank D.G.:'The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy". Am. J. Clin. Oneal., 1990, 13, 4.

[8] Eltabbakh G.H., Piver M.S., Hempling R.E., Recio F.O., Intengen M.E.: "Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma". J. Surg. Oneal., 1999, 70, 6.

[9] Markman M., Kelsen D.: "Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma". J. Cancer Res. Clin. Oncol., 1992, 118, 547.

[10] Feldman A.L., Libutti S.K., Pingpank J.F., Bartlett D.L., Beresnev T.H., Mavroukakis S.M., Steinberg S.M., Liewehr D.J., Kleiner D.E., Alexander H.R.: "Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical de bulking and intraperitoneal chemotherapy". J. Clin. Oneal., 2003, 21, 4560.

[11] Lee J.M., Bruckner H.W., Szrajer L., Brenne U., Schindelheim G., Andreotti P.E.: "Taxol inhibits growth of mesothelioma xenografts". Anticancer Res., 1995, 15, 693.

[12] Sugarbaker P.H., Acherman Y.I., Gonzalez-Moreno S., OrtegaPerez G., Stuart 0.A., Marchettini P., Yoo D.: "Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience". Semin. Oncol., 2002, 29, 51.

Submission Turnaround Time

Top